Harnessing Innate Immunity for the
Treatment of Cancer and Inflammatory Disorders

OUR MISSION

At IFM Therapeutics, we are driven to invent transformative therapies to improve the lives of patients with serious, life threatening diseases.

We are passionate about building a company that embraces creativity, integrity, and excellence.

OUR APPROACH

TARGETING INNATE IMMUNE SYSTEM ACTIVITY

Cancer Measure
Inflamatory Measure

Diseased State

Therapeutic Potential

THE COMPANY

IFM Therapeutics was incubated as part of the Atlas Venture seed program in 2015. In June 2016, we announced a $27M series A financing led by Atlas Venture and Abingworth, with participation from Novartis.

TEAM

NEWS & EVENTS

IFM Therapeutics Appoints H. Martin Seidel as Executive Vice President of Research and Development

Read more: Press Release

IFM Therapeutics Appoints Renowned Physicians from Academia and Industry to Clinical Advisory Board

Read more: Press Release

IFM Therapeutics Establishes German Subsidiary and Research Site

Read more: Press Release

IFM Offices Move to 855 Boylston St. Boston, MA 02116

IFM Therapeutics Appoints Leading Oncology, Immunology, and Chemistry Experts to Founding Scientific Advisory Board

Read more: Press Release

IFM Therapeutics appoints Ed Olhava as Senior Vice President of Drug Discovery

Read more: Biography

IFM Therapeutics Raises $27 Million Series A Financing Led by Atlas Venture and Abingworth

Read more: Press Release, BioCentury (subscription required), BioWorld (subscription required), ENDPOINTS, FierceBiotech, Wall Street Journal Pro (subscription required), and Xconomy

CONTACT US

HEADQUARTERS

855 Boylston Street, 11th Floor
Boston, MA 02116

EMAIL